Discover
DNTH
Dianthus Therapeutics, Inc.
90.21
2 x 69.61
2 x 115.58
bid
ask
-
7.27
7.46%
2 @ 04:00 AM
91.82 +1.61 (1.78%)
| Ytd | 118.90% | |
| 1y | 402.28% |
90.08
day range
97.55
17.88
52 week range
98.70
| Open | 96.68 | Prev Close | 97.48 | Low | 90.08 | High | 97.55 | Mkt Cap | 4.93B |
| Vol | 1.61M | Avg Vol | 900.76K | EPS | -4.23 | P/E | N/A | Forward P/E | -19.40 |
| Beta | 0.07 | Short Ratio | 7.33 | Inst. Own | 120.45% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 86.71 | 200-d Avg | 59.86 | 1yr Est | 127.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-03 | 0 | N/A | 0.32 | 27.35% |
| 2026-03-09 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-05 | 2025-09 | 0 | N/A | -0.11 | -12.79% |
| 2025-11-05 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-07 | 2025-06 | 0 | N/A | -0.02 | -2.33% |
| 2025-08-07 | 2025-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-06 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-04-09 | Wolfe Research | Upgrade | Outperform | |
| 2026-03-19 | Wells Fargo | Upgrade | Overweight | |
| 2026-03-12 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-03-10 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-03-10 | Raymond James | Upgrade | Outperform | Strong Buy |
Profile
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-03-11 | CARR EDWARD | Officer | 0.00 | Sale |
| 2026-03-15 | GARCIA MARINO | Chief Executive Officer | 65.29K | Conversion of Exercise of derivative security |
| 2026-05-31 | RANDHAWA SIMRAT | Officer | 4.00K | Sale |
| 2026-04-08 | SAVITZ RYAN | Chief Financial Officer | 0.00 | Sale |
| 2026-05-07 | SOTEROPOULOS PAULA | Director | 0.00 | Sale |
| 2026-06-16 | VENESS ADAM M | General Counsel | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 7.77M | 700.72M | 14.21% |
| 2026-03-30 | Blackrock Inc. | 3.18M | 286.48M | 5.81% |
| 2026-03-30 | RA Capital Management, L.P. | 2.61M | 235.60M | 4.78% |
| 2026-03-30 | Wellington Management Group, LLP | 2.60M | 234.17M | 4.75% |
| 2026-03-30 | Fairmount Funds Management LLC | 2.54M | 228.88M | 4.64% |
| 2026-03-30 | Avidity Partners Management, LP | 2.10M | 189.82M | 3.85% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.59M | 143.81M | 2.92% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.57M | 141.22M | 2.86% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.24M | 112.27M | 2.28% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 843.58K | 76.10M | 1.54% |
| 2026-05-30 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 730.06K | 65.86M | 1.34% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 649.41K | 58.58M | 1.19% |